Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-25T14:30:28.441Z Has data issue: false hasContentIssue false
  • English
  • Français

The Treatment of Lymphomas with Vincaleukoblastine and Methylhydrazine

Published online by Cambridge University Press:  01 August 2014

E. Anglesio ,
A. Calciati  and
V. Caramello
E. Anglesio
Affiliation:
Istituto di Oncologia, Ospedale di S. Giovanni e della Città di Torino
A. Calciati
Affiliation:
Istituto di Oncologia, Ospedale di S. Giovanni e della Città di Torino
V. Caramello
Affiliation:
Istituto di Oncologia, Ospedale di S. Giovanni e della Città di Torino

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Results of Chemotherapic treatment in Hodgkin's disease are reported. 23 cases were treated by Vincaleucoblastine, 19 by Methylhydrazine, and 12 by both drugs. With VLB we obtained 6 complete remissions, 12 partial remissions and 5 failures; with MH the remissions were 9 complete, 4 partial and 6 failures. An improvement was obtained by the use of both drugs successively administered and repeatedly.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 232 - 244
Copyright
Copyright © The International Society for Twin Studies 1968

References

Anglesio, E. (1965). Trattamento della malattia di Hodgkin con il Natulan. Minerva Med., 56: 100.Google Scholar
Armstrong, J. et al. (1962). Hodgin's disease, carcinoma of the breast and other tumors treated with Vinblastine sulfate. Cancer Chemother. Rep., 18.Google Scholar
Bernard, J. et al. (1964). Traitement de la maladie de Hodgkin par la Vincaleucoblastine. Presse Med., 72: 1471.Google Scholar
Berteis, K. et al. (1963). Der pro-oxydative effect tumorhemmender Methyl-Hydrazin-verbindungen. Helv. Chim. Acta 6: 2157.Google Scholar
Bollag, W. (1963). The tumor-inhibitory effects of the methylhydrazine derivative Ro-4-6467. Cancer Chemother. Rep., 33: 1.Google Scholar
Brunner, K. W., Young, C. V. (1965). A methylhydrazine derivative in Hodgkin's disease and other malignant neoplasms. Ann. Intern. Med., 63–69.Google Scholar
Cook, J. C. et al. (1959). Combined radiation and nitrogen mustard therapy in Hodgkin's disease as compared with radiation therapy alone. Ann. J. Roentg., 82: 651.Google ScholarPubMed
D'Alessandri, A. et al. (1963). Erste klinische Erfahrungen mit einem neuen Cytostaticum. Schweiz. Med. Wschr., 93: 1018.Google Scholar
Diamond, H. D. (1958). The Medical Management of Cancers. Grune & Stratton Ed.Google Scholar
Gellhorn, A., a. Collins, V. P. (1951). A quantitative evaluation of the contribution of nitrogen mustard to the therapeutic management of Hodgkin disease. Ann. Intern. Med., 35: 1250.Google Scholar
Gerhartz, H. (1964). Chemotherapy of Cancer - Clinical Results with Cyclosphosphamid and Trisethylene Iminoquinone 62. Elsevier, Amsterdam.Google Scholar
Grifoni, V. et al. (1965). Stato attuale della terapia della malattia di Hodgkin. Recent Progr. Med., 39: 585.Google Scholar
Hill, J. M., Loeb, E. (1962). Treatment of leukemia, lymphoma and other malignant neoplasms with Vinblastine. Cancer. Chemother. Rep., 15.Google Scholar
Hodes, M. E. et al. (1960). Vincaleucoblastine - Preliminary clinical studies. Cancer Res., 20: 1041.Google Scholar
Karnofsky, D. A. (1965). Hodgkin's disease - Chemotherapy. J.A.M.A., 191: 30.Google Scholar
Keiser, G. et al. (1962). Klinische Erfahrungen mit Vincaleukoblastin (Velbe) einem neuem Cytostaticum. Schweiz. Med. Wschr., 92: 486.Google Scholar
Kenis, Y. et al. (1965). Action d'un dérivé de la Méthylhydrazine, le RO4-6467, dans la Maladie de Hodgkin, dans d'autres lymphomes malins et dans des leucémies. Europ. J. Cancer, 1: 33.CrossRefGoogle Scholar
Linke, A. (1960). Die Behandlung der Hämoblastosen und maligner Tumoren mit Trisäthylenimins benzochinon. Deut. Med. Woch. 85: 1928.Google Scholar
Martz, G. et al. (1963). Preliminary clinical results with anew antitumor agent: Ro4-6467. Cancer Chemother. Rep., 33.Google Scholar
Marsden, J. A. (1963). Report on the use of vincaleucoblastine in 14 cases of Hodgkin's disease. Med. J Aust., 2: 100.CrossRefGoogle Scholar
Mathé, G. et al. (1962). Essai de traitement de la maladie de Hodgkin et d'autres affections réticulo-histiocytaires malignes par la Vincaleucoblastine. Presse Med., 70: 1349.Google Scholar
Matthias, J. Q. et al. (1960). Cyclosphosphamide in Hodgkin's disease and related disorders. Brit. Med. J., 11: 1837.CrossRefGoogle Scholar
Obreckt, P. (1964). Chemotherapy of Cancer — Vinca Alkaloids 165. Elsevier, Amsterdam.Google Scholar
Rousso, C. H. (1961). Le traitement de la maladie de Hodgkin par des cures brèves de moutard à l'azote. Helv. Med. Acta, 28: 99.Google Scholar
Scott, J. L. (1963). The effect of nitrogen mustard and maintenance chlorambucil in the treatment of advanced Hodgkin's disease. Cancer Chemather. Rep., 77: 27.Google Scholar
Spurr, C. L. et al. (1950). The role of nitrogen mustard therapy in the treatment of lymphomas and leukemias. Amn. J. Med., 8: 710.Google Scholar
Ultmann, J. E. (1966). Chemioterapia del linfoma. Aggiornamenti in Ematologia, 3: 203.Google Scholar
Warwick, H. O. et al. (1961). Clinical experience with vinblastine sulfate. Canad. Med. Ass. J., 85: 579.Google Scholar
Whitelaw, D. M., Teasdale, J. M. (1961). Vincaleukoblastine in the treatment of malignant disease. Canad. Med. Ass. J., 85: 854.Google Scholar
Wilmanns, H. (1964). Chemotherapie Maligner Tumoren. F. K. Schattauer Ed., Stoccarda.Google Scholar
Wintrobe, M. M., Huguley, C. M. (1948). Nitrogen mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias and other diseases. Cancer, 1: 357.3.0.CO;2-V>CrossRefGoogle Scholar
Williams, H. M. et al. (1959). Neurological Complications of Lymphomas and Leukemias. C. C. Thomas, Springfield.Google Scholar
Zeller, P. et al. (1963). Methylhydrazine derivatives. A new class of cytotoxic agent. Experientia, 19: 129.CrossRefGoogle Scholar